UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 1,719 Shares of Transcat, Inc. (NASDAQ:TRNS)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC cut its stake in shares of Transcat, Inc. (NASDAQ:TRNS) by 11.1% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 13,722 shares of the scientific and technical instruments company’s stock after selling 1,719 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Transcat were worth $1,657,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the stock. Conestoga Capital Advisors LLC lifted its position in shares of Transcat by 17.9% during the 3rd quarter. Conestoga Capital Advisors LLC now owns 907,191 shares of the scientific and technical instruments company’s stock valued at $109,561,000 after buying an additional 137,830 shares in the last quarter. Calamos Advisors LLC raised its stake in Transcat by 76.0% during the 2nd quarter. Calamos Advisors LLC now owns 15,441 shares of the scientific and technical instruments company’s stock worth $1,848,000 after acquiring an additional 6,667 shares during the period. Millrace Asset Group Inc. purchased a new position in Transcat during the third quarter valued at approximately $655,000. Champlain Investment Partners LLC boosted its position in shares of Transcat by 22.1% in the third quarter. Champlain Investment Partners LLC now owns 409,500 shares of the scientific and technical instruments company’s stock worth $49,455,000 after purchasing an additional 74,169 shares during the period. Finally, First Horizon Advisors Inc. increased its stake in shares of Transcat by 26.4% in the second quarter. First Horizon Advisors Inc. now owns 599 shares of the scientific and technical instruments company’s stock worth $72,000 after purchasing an additional 125 shares in the last quarter. Institutional investors own 98.34% of the company’s stock.

Transcat Trading Up 0.1 %

NASDAQ:TRNS opened at $109.21 on Tuesday. The company has a market capitalization of $1.00 billion, a P/E ratio of 55.16 and a beta of 0.70. The business’s 50-day moving average is $111.17 and its 200 day moving average is $119.18. Transcat, Inc. has a 12 month low of $94.29 and a 12 month high of $147.12.

Transcat (NASDAQ:TRNS) last issued its quarterly earnings data on Monday, October 28th. The scientific and technical instruments company reported $0.35 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.47 by ($0.12). Transcat had a return on equity of 7.36% and a net margin of 6.63%. The firm had revenue of $67.83 million for the quarter, compared to analysts’ expectations of $70.30 million. During the same period last year, the company earned $0.41 earnings per share. The firm’s revenue was up 8.0% on a year-over-year basis. On average, research analysts forecast that Transcat, Inc. will post 1.76 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on TRNS shares. HC Wainwright restated a “buy” rating and set a $156.00 target price on shares of Transcat in a research note on Tuesday, October 29th. Oppenheimer reaffirmed an “outperform” rating and issued a $130.00 price objective (down previously from $155.00) on shares of Transcat in a research note on Wednesday, October 30th. Northland Securities decreased their target price on Transcat from $130.00 to $110.00 and set a “market perform” rating on the stock in a research note on Wednesday, October 30th. StockNews.com downgraded Transcat from a “hold” rating to a “sell” rating in a research note on Tuesday, October 29th. Finally, Craig Hallum increased their price objective on shares of Transcat from $113.00 to $125.00 and gave the company a “buy” rating in a report on Thursday, December 12th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $130.25.

Transcat Profile

Transcat, Inc provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services.